Boehringer Ingelheim and Envisagenics sign oncology collaboration worth more than $1bn
Boehringer Ingelheim and Envisagenics have entered a multi-year oncology collaboration worth more than $1 billion to discover therapeutic targets created by alternative RNA splicing.
The partnership will use Envisagenics' AI-powered SpliceCore platform to identify tumour-specific RNA-splicing targets for potential ADCs, T-cell engagers and multispecific antibodies.
Envisagenics is eligible for more than $1 billion in potential payments plus royalties, providing major validation for its precision-oncology discovery platform.
Field | Content |
Alert Type | Deal |
Companies | Boehringer Ingelheim; Envisagenics |
Deal Type | Multi-year oncology discovery collaboration |
Asset or Company | SpliceCore platform |
Therapy Area(s) | Oncology; hard-to-treat cancers |
Technology or Modality | AI-powered RNA splicing target discovery; ADCs; T-cell engagers; multispecific antibodies |
Deal Value | More than US$1 billion in potential payments plus royalties |
Geography | Global |
What Happened | Boehringer Ingelheim and Envisagenics entered a multi-target collaboration to discover tumour-specific targets arising from alternative RNA splicing. |
Why It Matters | Alternative RNA splicing can generate cancer-specific targets that are not present in healthy tissue, potentially enabling more selective precision therapies. |
Supporting Context | Envisagenics' SpliceCore platform uses artificial intelligence to identify disease-associated RNA-splicing events and translate them into therapeutic targets. |
Strategic Rationale | Boehringer gains access to a differentiated oncology target-discovery platform while Envisagenics receives significant milestone and royalty economics. |
Potential Impact | The collaboration could generate new targeted therapies for cancers that remain difficult to treat with existing modalities. |
Key Takeaway | Boehringer Ingelheim is partnering with Envisagenics in an oncology collaboration carrying more than US$1 billion in potential value. |
What to Watch | Target selection, validation of RNA-splicing-derived targets and advancement of resulting programmes into preclinical development. |
Primary Source | Envisagenics |
Relevant Date | 22 September 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Kommentare